SK Chemical-PharmaResearch Jointly Launch 'Conjuran' Co-Promotion

SK Chemicals announced on the 3rd that it will jointly promote Pharmaresearch's 'Conjuranju'. (Photo by SK Chemicals)

[Asia Economy Reporter Lee Chun-hee] SK Chemicals is collaborating with PharmaResearch to sell intra-articular injection products in the osteoarthritis field.

On the 3rd, SK Chemicals announced that it has signed an agreement with PharmaResearch to implement a co-promotion for marketing and sales targeting general hospitals to increase the domestic market share of 'Conjuran,' an intra-articular injection (medical device).

Through this co-promotion, SK Chemicals has completed its portfolio of osteoarthritis treatment products by adding Conjuran, an intra-articular injection, following the osteoarthritis treatments Joins tablets and Trust patches. PharmaResearch also expects to expand the market share of Conjuran by partnering with SK Chemicals, which has excellent marketing capabilities in the musculoskeletal field.

Conjuran contains highly viscous polydeoxyribonucleotide sodium, which maintains a certain form when injected into the knee joint cavity, reducing joint friction and pain. Polydeoxyribonucleotide sodium has been used in Europe for over 10 years, and its safety and efficacy have been proven through clinical data.

Conjuran, launched domestically in 2019, has had its insurance coverage expanded since March last year for patients with knee osteoarthritis, allowing more patients to benefit. The domestic intra-articular injection market was estimated to be about 100 billion KRW last year.

Choi Beom, Marketing Director at PharmaResearch, said, "Conjuran's base expanded last year due to insurance coverage, leading new changes in the intra-articular injection market,” adding, “Based on SK Chemicals' marketing capabilities and know-how, we expect to further increase domestic market share.” Kim Jung-hoon, Head of Pharma Planning at SK Chemicals, also said, “This co-promotion will further strengthen SK Chemicals' position in the musculoskeletal field,” and “At the same time, through synergy with existing products, it will contribute to improving patients' quality of life.”